OriGene Technologies Raises $30 Million to Revolutionize Genomic Research Tools

OriGene Technologies, a leader in the field of genomic research tools, has announced a significant funding achievement, successfully raising $30 million in its latest funding round. Founded with a mission to provide the largest commercial collection of full-length human cDNAs, OriGene has pioneered the development of innovative platforms that empower scientists to delve into the complexities of biological pathways, enhancing the understanding of disease mechanisms including cancer and stem cell research. This latest influx of capital will be strategically utilized to expand OriGene’s comprehensive product offerings, which include over 30,000 full-length TrueClone cDNA collections and a vast repository of TrueORF cDNA clones. The funding will additionally support OriGene's next phase of growth—enhancing its flagship TrueMAB project that aims to develop mouse monoclonal antibodies for every human protein, thus facilitating advanced protein assays essential for modern medical research. Furthermore, this investment will bolster the company’s capabilities in biomarker discovery and validation through unique gene expression products such as TissueScan cancer tissue qPCR arrays. OriGene is renowned for its high-throughput, genome-wide approach, which serves pharmaceutical, biotechnology, and academic researchers alike. With this funding, OriGene Technologies reaffirms its commitment to becoming “Your Gene Company,” ensuring that researchers worldwide have access to cutting-edge gene-based research tools. As it continues to innovate and expand its offerings, OriGene aims to revolutionize how scientific inquiries are conducted, propelling advances that could lead to transformative breakthroughs in healthcare. For more information about our products and initiatives, visit us at [OriGene Technologies](https://www.origene.com).